Todas las investigaciones
ReclutamientoFASE3INTERVENCIONISTA

ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

This research study is investigating a new gene therapy called ATSN-201 for an inherited eye condition known as X-linked Retinoschisis (XLRS). XLRS affects the retina, the light-sensitive layer at the back of your eye, leading to vision problems. This study wants to find out if ATSN-201 is both safe to use and whether it can improve vision or slow down the progression of XLRS in people aged 6 and older. The treatment involves a one-time injection into the eye. Some people in the study will receive the treatment, while others won't at first, but may have the option later. Your participation could help scientists understand if this new therapy could be a future treatment option for XLRS.

De un vistazo

Estado
Reclutamiento
Fase
FASE3
Patrocinador
Atsena Therapeutics Inc.
Objetivo de inscripción
97
Inicio
22 Ago 2023
Estimación de finalización
01 Apr 2033

¿De qué trata este estudio?

This study is looking into a new treatment called ATSN-201 for a condition called X-linked Retinoschisis, or XLRS. XLRS is a rare, inherited eye condition that mainly affects boys and men. It happens because of a problem with a specific gene (RS1), which causes layers of the retina – the light-sensitive tissue at the back of your eye – to split. This splitting can lead to blurry vision and sometimes more severe vision loss.

ATSN-201 is a type of 'gene therapy'. This means it aims to correct the underlying genetic problem causing XLRS. The idea is to deliver a healthy version of the RS1 gene into the eye, which hopefully will help the retina work better and prevent further vision problems. The study will carefully check if this treatment is safe and if it helps improve or stabilise vision in people with XLRS.

The study is divided into different parts. In one part, people will be randomly chosen to either receive the ATSN-201 treatment or to be in a group that doesn't get the treatment initially. Those who receive the treatment will have a single injection into one or both eyes, depending on their specific eye condition. Everyone involved will have regular check-ups over a year, and then follow-up for another four years to see how they are doing in the long term. This careful approach helps the researchers understand the full effects of the treatment.

Puntos clave

  • This study investigates a new gene therapy (ATSN-201) for X-linked Retinoschisis (XLRS).
  • It aims to check the safety and effectiveness of the treatment in people aged 6 and over.
  • The treatment involves a one-time injection into the eye.
  • Participation includes regular check-ups over a period of about five years.
  • Some participants will receive the treatment, while others may get it later.
  • This research could help develop future treatments for XLRS.

¿Quién puede ser elegible?

To join this study, participants generally need to be male and have been diagnosed with X-linked Retinoschisis (XLRS) caused by a problem with the RS1 gene. They need to be at least 6 years old. Your vision in the eye being studied will also need to be within a certain range – not too good, but not severely poor either. Doctors will check for specific signs of the condition in your eye, like splitting in certain areas of the retina.

There are also reasons why someone might not be able to join. For example, if you have other serious eye conditions that could make the treatment risky, or if you've had eye surgery recently. Also, if you've previously had other types of gene or cell therapy for your eyes, you wouldn't be able to take part in this particular study. The study team will review all your medical information carefully to see if it's safe and appropriate for you to participate.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. Are you male and diagnosed with X-linked Retinoschisis (XLRS)?
  2. Is your XLRS caused by a problem with the RS1 gene?
  3. Are you 6 years old or older?
  4. Is your vision in the affected eye within a specific range (not too good or too bad)?
  5. Do you have signs of retinal splitting in your eye as seen by a doctor?
  6. Have you *not* had recent eye surgery or other gene therapies for your eyes?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you decide to take part, the study involves several steps. First, doctors will check if you're suitable to join. If you are, you'll be assigned to either receive the ATSN-201 treatment or to a group that doesn't get the treatment straight away. If you receive the treatment, it will be given as a single injection into one or both of your eyes.

After this, you'll have regular hospital visits and check-ups for about one year to see how you're responding and to monitor your eye health. These checks might include eye exams, vision tests, and scans of your retina. Following this initial year, there will be further check-ups over the next four years to see the long-term effects of the treatment. If you were in the group that didn't receive the treatment initially, you might have the option to receive it after the first year, if you're still eligible. The total study duration, including follow-up, could be around five years.

Riesgos y beneficios potenciales

Participating in any study has potential benefits and risks. A potential benefit of taking part in this study is that ATSN-201 might improve your vision or slow down the progression of your XLRS, although this is not guaranteed as it's a new treatment being tested. There are also potential risks associated with the eye injection, such as infection, bleeding, or changes in eye pressure. The study team will explain all known risks to you in detail. Remember, your participation is completely voluntary, and you are free to withdraw from the study at any time without affecting your usual medical care.

Locations (21)

  • Associated Retina Consultants
    Código postal verificado
    Phoenix, Estados Unidos· Reclutamiento
  • Shiley Eye Institute
    Código postal verificado
    La Jolla, Estados Unidos· Aún no reclutando
  • Children's Hospital of Los Angeles
    Código postal verificado
    Los Angeles, United States· Reclutamiento
  • Stanford University
    Código postal verificado
    Palo Alto, Estados Unidos· Aún no reclutando
  • UC San Francisco
    Código postal verificado
    San Francisco, Estados Unidos· Reclutamiento
  • Bascom Palmer Eye Institute
    Código postal verificado
    Miami, United States· Reclutamiento
  • Massachusetts Eye and Ear
    Código postal verificado
    Boston, Estados Unidos· Reclutamiento
  • Boston Children's Hospital
    Código postal verificado
    Boston, Estados Unidos· Aún no reclutando
  • University of Michigan
    Código postal verificado
    Ann Arbor, Estados Unidos· Reclutamiento
  • Mayo Clinic
    Código postal verificado
    Rochester, United States· Reclutamiento
  • Columbia University
    Código postal verificado
    Nueva York, Estados Unidos· Reclutamiento
  • Flaum Eye Institute, University of Rochester
    Código postal verificado
    Rochester, United States· Aún no reclutando

Preguntas comunes

What is X-linked Retinoschisis (XLRS)?

XLRS is a rare, inherited eye condition that causes layers of the retina (the light-sensitive part at the back of your eye) to split, leading to vision problems.

¿Qué es la terapia génica?

Gene therapy is a new type of treatment that aims to fix the underlying genetic cause of a disease, in this case, by delivering a healthy gene into the eye.

Will I definitely get the treatment if I join?

Not everyone will get the active treatment straight away. Some participants will be in a group that receives the treatment, while others will be in a comparison group. However, those in the comparison group may have the option to receive the treatment later.

¿Cómo se administra el tratamiento?

The treatment, ATSN-201, is given as a single injection into the eye, specifically under the retina.

¿Cuánto tiempo estaré involucrado en el estudio?

You will have regular checks for one year after the treatment, followed by additional checks over the next four years, making it a commitment of around five years.

Cómo obtener más información

Atsena Therapeutics Clinical Trials

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschis…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.